

SUPPLEMENTARY EUROPEAN SEARCH REPORT

Application Number EP 03 72 3701

		ERED TO BE RELEVANT Indication, where appropriate,	Relevant	CLASSIFICATION OF THE
Category	of relevant pass	, , , ,	to claim	APPLICATION (IPC)
А	inhibition in the r silenced in cancer" NATURE GENETICS, NE	histone deacetylase re-expression of gene W YORK, NY, US, wary 1999 (1999-01), 12955246	1-18	INV. C12Q1/68 C12P19/34 C07H21/04
A	WO 01/77377 A2 (EPI ALEXANDER [DE]; PIE [DE];) 18 October 2 * the whole documer	2001 (2001-10-18)	1-18	
Α	maturation induced acids: Comparison w	thways of colonic cell by short chain fatty with trichostatin A, min and implications of colon cancer" 10-08-15), pages 1262	1-18	TECHNICAL FIELDS SEARCHED (IPC)
Α	human gastric carci CANCER RESEARCH, vol. 61, no. 11, 1 pages 4628-4635, XF * the whole documer	exygenase-2 by If the 5' CpG island in In noma cells" June 2001 (2001-06-01), In open cells to the control of the cells to the cells t	1-18	
	The supplementary search reposet of claims valid and available	rt has been based on the last at the start of the search.		
	Place of search	Date of completion of the search		Examiner
	The Hague	20 June 2007	Sa	ntagati, Fabio
X : parti Y : parti docu A : tech O : non	ATEGORY OF CITED DOCUMENTS icularly relevant if taken alone icularly relevant if combined with anotiment of the same category nological background written disolosure mediate document	L : document cited fo	cument, but pub e n the application or other reasons	ished on, or

EPO FORM 1503 03.82 (P04C04)

3



CLAIMS INCURRING FEES
The present European patent application comprised at the time of filing more than ten claims.
Only part of the claims have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims and for those claims for which claims fees have been paid, namely claim(s):
No claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims.
LACK OF UNITY OF INVENTION
The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:
see sheet B
All further search fees have been paid within the fixed time limit. The present European search report has been drawn up for all claims.
As all searchable claims could be searched without effort justifying an additional fee, the Search Division did not invite payment of any additional fee.
Only part of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the inventions in respect of which search fees have been paid, namely claims:
None of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the invention first mentioned in the claims, namely claims: 1-8 completely and 9-18 partially



LACK OF UNITY OF INVENTION SHEET B

Application Number

EP 03 72 3701

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

1. claims: 1-8 completely and 9-18 partially

A method of identifying at least one methylation silenced gene associated with at least one cancer, comprising: a) contacting an array of nucleotide sequences representative of a genome with nucleic acid subtraction products, which comprise nucleic acid molecules corresponding to RNA expressed in cancer cells contacted with a demethylating agent but not nucleic acid molecules corresponding to RNA expressed in normal cells corresponding to the cancer cells, under conditions suitable for selective hybridization of nucleic acid subtraction products to complementary nucleotide sequences of the array; and b) detecting selective hybridization of nucleic acid subtraction products to a subpopulation of nucleotide sequences of the array.

2. claims: 9-18 partially

A method of identifying at least one deacetylation silenced gene associated with at least one cancer, comprising: a) contacting an array of nucleotide sequences representative of a genome with nucleic acid subtraction products, which comprise nucleic acid molecules corresponding to RNA expressed in cancer cells contacted with at least one agent that reactivates expression of deacetylation silenced genes but not RNA expressed in normal cells corresponding to the cancer cells, under conditions suitable for selective hybridization of nucleic acid subtraction products to complementary nucleotide sequences of the array; and b) detecting selective hybridization of nucleic acid subtraction products to a subpopulation of nucleotide sequences of the array.

3. claims: 19-62

A method for identifying a cell that exhibits or is predisposed to exhibiting unregulated growth, comprising detecting, in a test cell, epigenetic silencing of at least one gene comprising a nucleic acid molecule as set forth in Table 1, or a combination thereof, thereby identifying the test cell as a cell that exhibits or is predisposed to exhibiting unregulated growth.

4. claims: 63-101



LACK OF UNITY OF INVENTION SHEET B

Application Number

EP 03 72 3701

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

An in vitro method for reducing or inhibiting unregulated growth of a cell exhibiting silenced transcription of at least one gene associated with cancer, comprising restoring expression of a polypeptide encoded by said gene; and the use of an agent in the manufacture of a medicament for treating cancer patient, wherein the agent is for restoring said polypeptide epxression.

5. claims: 102-116

Isolated or combined oligonucleotides, comprised in SEQ ID NOS: 1 to 296 and a kit containing said oligonucleotides.

ANNEX TO THE EUROPEAN SEARCH REPORT ON EUROPEAN PATENT APPLICATION NO.

EP 03 72 3701

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

20-06-2007

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
more details about this anne.	A2	18-10-2001	A A A A A A A A W W W W W E E E E E E P P P P P S S S S S S S S S	353975 T 5478801 A 5479401 A 7566301 A 7633001 A 7633101 A 7748701 A 8960001 A 0177375 A2 0177164 A2 0177376 A2 0181622 A2 0192565 A2 0177378 A2 0176451 A2 1268857 A2 1278893 A2 1274865 A2 1274866 A2 1360319 A2 1370685 A2 1268861 A2 2004508807 T 2003531589 T 2003082609 A1 2003162194 A1 2003148326 A1 2004067491 A1 2003148327 A1 2004076956 A1 2005282157 A1	15-03-20 23-10-20 23-10-20 23-10-20 23-10-20 23-10-20 07-11-20 11-12-20 18-10-20 18-10-20 18-10-20 18-10-20 18-10-20 18-10-20 18-10-20 18-10-20 15-01-20 15-01-20 15-01-20 15-01-20 12-11-20 02-01-20 25-03-20 25-11-20 01-05-20 28-08-20 07-08-20 07-08-20 22-04-20 22-12-20



专利名称(译)	用于与癌症相关的表观遗传学沉默	基因的基因组筛选	
公开(公告)号	EP1497462A4	公开(公告)日	2007-11-07
申请号	EP2003723701	申请日	2003-03-07
[标]申请(专利权)人(译)	约翰霍普金斯大学		
申请(专利权)人(译)	约翰·霍普金斯大学医学院		
当前申请(专利权)人(译)	约翰·霍普金斯大学医学院		
[标]发明人	BAYLIN STEPHEN B HERMAN JAMES G SUZUKI HIROMU SIDRANSKY DAVID		
发明人	BAYLIN, STEPHEN, B. HERMAN, JAMES, G. SUZUKI, HIROMU SIDRANSKY, DAVID		
IPC分类号	G01N33/53 A61K31/7068 A61K38 /02 C12Q1/34 C12Q1/68 G01N37		IP35/00 C12M1/00 C12N15/09 C12Q1
CPC分类号	C12Q1/6886 C12Q1/6809 C12Q2	600/154	
代理机构(译)	LEE , NICHOLAS JOHN		
优先权	60/362422 2002-03-07 US		
其他公开文献	EP1497462A2		
外部链接	Espacenet		

摘要(译)

提供了一种在癌细胞中鉴定表观遗传学沉默的基因,例如甲基化沉默的基因的方法。 另外,提供了通过检测基因表达的表观遗传沉默来鉴定癌症的方法,以及治疗患有这种癌症的受试者例如结肠直肠癌和/或胃癌的方法。 还提供了用于实践此类方法的试剂。

Category	Citation of document with in of relevant pass	ndication, where appropriate,	Relevant to glaim	CLASSIFICATION OF THE APPLICATION (IPC)	
А	CAMERON E E ET AL: dementhylation and inhibition in the r silenced in cancer NATURE GENETICS. NE	"Synergy of histone deacetylase e-expression of gene W YORK, NY, US, wary 1999 (1999-01), 2955246	1-18	1NV. C12Q1/68 C12P19/34 C07H21/04	
А	WO 01/77377 A2 (EPI ALEXANDER [DE]; PIE [DE];) 18 October 2 * the whole documen	GENOMICS AG [DE]; OLE PENBROCK CHRISTIAN 2001 (2001-10-18) ht *	K 1-18		
Α	MARIADASON J.M. ET AL.: "Genetic reprogramming in FAL.: "Genetic reprogramming in FAL.: "Genetic cell market and the state of the state		1-18		
	for chemoprevention CANCER RESEARCH, vol. 60, no. 16, 15 August 2000 (206 4561-4572, XP002438 * the whole documen		TECHNICAL FIELDS SEARCHED (IPC) C12Q		
A	SONG S.H. ET AL. "Transcriptional silencing of Cycloxygenase-2 by hyper-methylation of the 5 'CpG island in human gastric carcinoma cells." CANCER RESEARCH. 1 June 2001 (2001-06-01), pages 4628-4635. XPOQ2438633 The whole document				
	The supplementary search report has been based on the last out of oldsime valid and available at the start of the search.			Examinee	
The Hague		20 June 2007		Santagati, Fabio	
X : part Y : part close A : tech	ATEGORY OF CITED DOCUMENTS loularly relevant if taken alone loularly relevant if combined with anot moent of the same category modified beginning mediate document	her D : document cite L : document cite	ed in the application and for other reasons		